Intrinsic value of BioTelemetry - BEAT

Previous Close

$50.35

  Intrinsic Value

$24.43

stock screener

  Rating & Target

str. sell

-51%

Previous close

$50.35

 
Intrinsic value

$24.43

 
Up/down potential

-51%

 
Rating

str. sell

We calculate the intrinsic value of BEAT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
(a)
   1
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -100.00
  37.70
  34.43
  31.49
  28.84
  26.45
  24.31
  22.38
  20.64
  19.08
  17.67
  16.40
  15.26
  14.24
  13.31
  12.48
  11.73
  11.06
  10.45
  9.91
  9.42
  8.98
  8.58
  8.22
  7.90
  7.61
  7.35
  7.11
  6.90
  6.71
  6.54
Revenue, $m
  0
  395
  531
  699
  900
  1,138
  1,415
  1,731
  2,089
  2,487
  2,927
  3,407
  3,926
  4,485
  5,083
  5,717
  6,388
  7,094
  7,836
  8,612
  9,423
  10,269
  11,150
  12,066
  13,019
  14,010
  15,039
  16,109
  17,220
  18,376
  19,578
Variable operating expenses, $m
 
  347
  455
  586
  745
  932
  1,150
  1,399
  1,680
  1,993
  2,339
  2,680
  3,089
  3,529
  3,999
  4,498
  5,026
  5,582
  6,165
  6,776
  7,414
  8,080
  8,773
  9,494
  10,244
  11,023
  11,833
  12,675
  13,549
  14,459
  15,404
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  0
  347
  455
  586
  745
  932
  1,150
  1,399
  1,680
  1,993
  2,339
  2,680
  3,089
  3,529
  3,999
  4,498
  5,026
  5,582
  6,165
  6,776
  7,414
  8,080
  8,773
  9,494
  10,244
  11,023
  11,833
  12,675
  13,549
  14,459
  15,404
Operating income, $m
  0
  48
  77
  112
  155
  206
  265
  333
  409
  494
  587
  726
  837
  956
  1,083
  1,219
  1,362
  1,512
  1,670
  1,836
  2,009
  2,189
  2,377
  2,572
  2,775
  2,987
  3,206
  3,434
  3,671
  3,917
  4,174
EBITDA, $m
  0
  120
  161
  212
  273
  345
  428
  524
  633
  753
  886
  1,032
  1,189
  1,359
  1,539
  1,732
  1,935
  2,149
  2,373
  2,608
  2,854
  3,110
  3,377
  3,655
  3,943
  4,243
  4,555
  4,879
  5,216
  5,566
  5,930
Interest expense (income), $m
  0
  11
  17
  24
  32
  43
  55
  69
  86
  104
  124
  147
  172
  199
  227
  258
  291
  325
  362
  400
  440
  482
  525
  571
  618
  667
  718
  771
  826
  884
  943
Earnings before tax, $m
  0
  37
  60
  89
  123
  163
  210
  263
  323
  390
  463
  579
  665
  758
  856
  961
  1,071
  1,187
  1,309
  1,436
  1,569
  1,707
  1,851
  2,001
  2,157
  2,319
  2,488
  2,663
  2,845
  3,034
  3,230
Tax expense, $m
  0
  10
  16
  24
  33
  44
  57
  71
  87
  105
  125
  156
  180
  205
  231
  259
  289
  320
  353
  388
  424
  461
  500
  540
  582
  626
  672
  719
  768
  819
  872
Net income, $m
  0
  27
  44
  65
  90
  119
  153
  192
  236
  285
  338
  423
  486
  553
  625
  701
  782
  866
  955
  1,048
  1,145
  1,246
  1,352
  1,461
  1,575
  1,693
  1,816
  1,944
  2,077
  2,215
  2,358

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  0
  722
  971
  1,277
  1,645
  2,081
  2,586
  3,165
  3,818
  4,547
  5,350
  6,228
  7,178
  8,200
  9,292
  10,451
  11,678
  12,969
  14,325
  15,744
  17,227
  18,773
  20,383
  22,059
  23,801
  25,612
  27,494
  29,449
  31,482
  33,594
  35,792
Adjusted assets (=assets-cash), $m
  0
  722
  971
  1,277
  1,645
  2,081
  2,586
  3,165
  3,818
  4,547
  5,350
  6,228
  7,178
  8,200
  9,292
  10,451
  11,678
  12,969
  14,325
  15,744
  17,227
  18,773
  20,383
  22,059
  23,801
  25,612
  27,494
  29,449
  31,482
  33,594
  35,792
Revenue / Adjusted assets
  0.000
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
Average production assets, $m
  0
  354
  477
  627
  807
  1,021
  1,269
  1,553
  1,874
  2,231
  2,625
  3,056
  3,522
  4,023
  4,559
  5,128
  5,730
  6,363
  7,029
  7,725
  8,452
  9,211
  10,001
  10,823
  11,678
  12,567
  13,490
  14,450
  15,447
  16,483
  17,561
Working capital, $m
  0
  -11
  -15
  -20
  -25
  -32
  -40
  -48
  -58
  -70
  -82
  -95
  -110
  -126
  -142
  -160
  -179
  -199
  -219
  -241
  -264
  -288
  -312
  -338
  -365
  -392
  -421
  -451
  -482
  -515
  -548
Total debt, $m
  0
  308
  438
  598
  790
  1,017
  1,281
  1,584
  1,925
  2,305
  2,724
  3,182
  3,678
  4,212
  4,782
  5,387
  6,027
  6,701
  7,409
  8,150
  8,924
  9,731
  10,571
  11,446
  12,355
  13,301
  14,283
  15,304
  16,365
  17,468
  18,615
Total liabilities, $m
  0
  377
  507
  667
  859
  1,086
  1,350
  1,652
  1,993
  2,373
  2,793
  3,251
  3,747
  4,280
  4,850
  5,456
  6,096
  6,770
  7,477
  8,218
  8,992
  9,799
  10,640
  11,515
  12,424
  13,369
  14,352
  15,372
  16,433
  17,536
  18,683
Total equity, $m
  0
  345
  464
  610
  786
  995
  1,236
  1,513
  1,825
  2,173
  2,557
  2,977
  3,431
  3,920
  4,441
  4,996
  5,582
  6,199
  6,847
  7,526
  8,234
  8,973
  9,743
  10,544
  11,377
  12,242
  13,142
  14,077
  15,048
  16,058
  17,108
Total liabilities and equity, $m
  0
  722
  971
  1,277
  1,645
  2,081
  2,586
  3,165
  3,818
  4,546
  5,350
  6,228
  7,178
  8,200
  9,291
  10,452
  11,678
  12,969
  14,324
  15,744
  17,226
  18,772
  20,383
  22,059
  23,801
  25,611
  27,494
  29,449
  31,481
  33,594
  35,791
Debt-to-equity ratio
  0.000
  0.890
  0.940
  0.980
  1.000
  1.020
  1.040
  1.050
  1.050
  1.060
  1.070
  1.070
  1.070
  1.070
  1.080
  1.080
  1.080
  1.080
  1.080
  1.080
  1.080
  1.080
  1.080
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
Adjusted equity ratio
  0.000
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  0
  27
  44
  65
  90
  119
  153
  192
  236
  285
  338
  423
  486
  553
  625
  701
  782
  866
  955
  1,048
  1,145
  1,246
  1,352
  1,461
  1,575
  1,693
  1,816
  1,944
  2,077
  2,215
  2,358
Depreciation, amort., depletion, $m
  0
  72
  84
  99
  117
  139
  163
  192
  224
  260
  299
  306
  352
  402
  456
  513
  573
  636
  703
  772
  845
  921
  1,000
  1,082
  1,168
  1,257
  1,349
  1,445
  1,545
  1,648
  1,756
Funds from operations, $m
  0
  99
  128
  164
  207
  258
  317
  384
  460
  544
  637
  728
  838
  955
  1,081
  1,214
  1,355
  1,503
  1,658
  1,821
  1,990
  2,167
  2,352
  2,543
  2,743
  2,950
  3,165
  3,389
  3,621
  3,863
  4,114
Change in working capital, $m
  0
  -3
  -4
  -5
  -6
  -7
  -8
  -9
  -10
  -11
  -12
  -13
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -29
  -30
  -31
  -32
  -34
Cash from operations, $m
  0
  102
  132
  169
  213
  265
  325
  393
  470
  555
  649
  742
  852
  971
  1,098
  1,232
  1,373
  1,523
  1,679
  1,842
  2,013
  2,191
  2,376
  2,569
  2,769
  2,978
  3,194
  3,419
  3,652
  3,895
  4,148
Maintenance CAPEX, $m
  0
  -26
  -35
  -48
  -63
  -81
  -102
  -127
  -155
  -187
  -223
  -263
  -306
  -352
  -402
  -456
  -513
  -573
  -636
  -703
  -772
  -845
  -921
  -1,000
  -1,082
  -1,168
  -1,257
  -1,349
  -1,445
  -1,545
  -1,648
New CAPEX, $m
  0
  -97
  -122
  -150
  -181
  -214
  -248
  -284
  -321
  -357
  -394
  -431
  -466
  -501
  -536
  -569
  -602
  -634
  -665
  -696
  -727
  -759
  -790
  -822
  -855
  -889
  -923
  -960
  -997
  -1,037
  -1,078
Cash from investing activities, $m
  0
  -123
  -157
  -198
  -244
  -295
  -350
  -411
  -476
  -544
  -617
  -694
  -772
  -853
  -938
  -1,025
  -1,115
  -1,207
  -1,301
  -1,399
  -1,499
  -1,604
  -1,711
  -1,822
  -1,937
  -2,057
  -2,180
  -2,309
  -2,442
  -2,582
  -2,726
Free cash flow, $m
  0
  -21
  -26
  -29
  -31
  -30
  -26
  -18
  -6
  11
  32
  49
  80
  117
  160
  207
  259
  316
  377
  443
  513
  587
  665
  747
  832
  921
  1,014
  1,110
  1,210
  1,314
  1,422
Issuance/(repayment) of debt, $m
  0
  104
  130
  160
  192
  227
  264
  302
  341
  380
  419
  458
  496
  533
  570
  605
  640
  674
  708
  741
  774
  807
  841
  875
  909
  945
  982
  1,021
  1,061
  1,103
  1,147
Issuance/(repurchase) of shares, $m
  0
  68
  75
  81
  86
  89
  88
  84
  76
  64
  46
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  0
  172
  205
  241
  278
  316
  352
  386
  417
  444
  465
  458
  496
  533
  570
  605
  640
  674
  708
  741
  774
  807
  841
  875
  909
  945
  982
  1,021
  1,061
  1,103
  1,147
Total cash flow (excl. dividends), $m
  0
  150
  179
  212
  248
  286
  327
  369
  411
  454
  497
  507
  577
  651
  729
  812
  899
  990
  1,085
  1,184
  1,287
  1,394
  1,506
  1,621
  1,742
  1,866
  1,996
  2,131
  2,271
  2,417
  2,568
Retained Cash Flow (-), $m
  0
  -94
  -119
  -146
  -176
  -208
  -242
  -277
  -312
  -348
  -384
  -419
  -454
  -488
  -522
  -554
  -586
  -617
  -648
  -678
  -709
  -739
  -770
  -801
  -833
  -866
  -900
  -935
  -972
  -1,010
  -1,050
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  8
  11
  14
  19
  24
  31
  38
  47
  56
  67
  79
  92
  106
  121
  137
  154
  172
  192
  212
  233
  254
  277
  301
  326
  352
  378
  406
  435
  465
  496
Cash available for distribution, $m
 
  56
  60
  66
  72
  78
  85
  92
  99
  106
  113
  87
  122
  162
  208
  258
  313
  373
  437
  506
  578
  655
  736
  820
  909
  1,001
  1,097
  1,196
  1,300
  1,407
  1,518
Discount rate, %
 
  7.10
  7.46
  7.83
  8.22
  8.63
  9.06
  9.51
  9.99
  10.49
  11.01
  11.57
  12.14
  12.75
  13.39
  14.06
  14.76
  15.50
  16.27
  17.09
  17.94
  18.84
  19.78
  20.77
  21.81
  22.90
  24.04
  25.25
  26.51
  27.83
  29.22
PV of cash for distribution, $m
 
  52
  52
  52
  52
  52
  50
  49
  46
  43
  40
  26
  31
  34
  36
  36
  35
  32
  29
  25
  21
  17
  14
  11
  8
  6
  4
  3
  2
  1
  1
Current shareholders' claim on cash, %
  100
  95.7
  92.4
  89.8
  87.7
  86.1
  84.8
  83.9
  83.2
  82.7
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4
  82.4

BioTelemetry, Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The company operates in three segments: Healthcare, Research, and Technology. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. It offers Mobile Cardiac Outpatient Telemetry and External Cardiac Ambulatory Telemetry services, which incorporates a lightweight patient-worn sensor attached to electrodes that capture two-channel electrocardiography (ECG) data, measuring electrical activity of the heart, on a compact wireless handheld monitor; event monitoring services to prescribe wireless event monitors, digital loop event monitors, memory loop event monitors, and non-loop event monitors; and a Holter and extended-wear Holter monitors to cardiologists and electrophysiologists. The Research Services segment provides cardiac monitoring, imaging, scientific consulting, and data management services for drug, medical treatment, and device trials to pharmaceutical companies and contract research organizations. Its centralized services include ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, and expert reporting and statistical analysis. This segment also offers services in the cardiovascular, oncology, musculoskeletal, and neurologic therapeutic areas; and support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Technology segment focuses on the manufacture, engineering, and development of non-invasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices, including cardiac event monitors, digital Holter monitors, and mobile cardiac telemetry monitors. BioTelemetry, Inc. is headquartered in Malvern, Pennsylvania.

FINANCIAL RATIOS  of  BioTelemetry (BEAT)

Valuation Ratios
P/E Ratio 0
Price to Sales 0
Price to Book 0
Price to Tangible Book
Price to Cash Flow 0
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio NaN
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 0%
Ret/ On Assets - 3 Yr. Avg. 0%
Return On Total Capital 0%
Ret/ On T. Cap. - 3 Yr. Avg. 0%
Return On Equity 0%
Return On Equity - 3 Yr. Avg. 0%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. 0%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. 0%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. 0%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. 0%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

BEAT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the BEAT stock intrinsic value calculation we used $287 million for the last fiscal year's total revenue generated by BioTelemetry. The default revenue input number comes from income statement of BioTelemetry. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our BEAT stock valuation model: a) initial revenue growth rate of 37.7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 7.1%, whose default value for BEAT is calculated based on our internal credit rating of BioTelemetry, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of BioTelemetry.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of BEAT stock the variable cost ratio is equal to 91.4%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for BEAT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for BioTelemetry.

Corporate tax rate of 27% is the nominal tax rate for BioTelemetry. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the BEAT stock is equal to 2.7%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for BEAT are equal to 89.7%.

Life of production assets of 10 years is the average useful life of capital assets used in BioTelemetry operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for BEAT is equal to -2.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $251 million for BioTelemetry - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 30 million for BioTelemetry is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of BioTelemetry at the current share price and the inputted number of shares is $1.5 billion.

COMPANY NEWS

▶ NovoCure (NVCR) Catches Eye: Stock Jumps 7.4%   [Jul-17-18 08:54AM  Zacks]
▶ [$$] Diabetes Monitoring Company ActiveCare Files for Bankruptcy   [Jul-16-18 02:22PM  The Wall Street Journal]
▶ Natera (NTRA) Catches Eye: Stock Jumps 6.3%   [Jul-13-18 08:49AM  Zacks]
▶ 18 Midterm Election Year Stock Picks   [Jul-09-18 07:23AM  Investopedia]
▶ Tech Rally Ends NASDAQ's 5-Day Slide   [Apr-27-18 09:15AM  Zacks]
▶ BioTelemetry: 1Q Earnings Snapshot   [Apr-25-18 05:32PM  Associated Press]
▶ Healthcare and biotech investor Sami Hamade dies   [Apr-09-18 04:54PM  American City Business Journals]
▶ BioTelemetry reports 4Q loss   [Feb-22-18 07:53PM  Associated Press]
▶ BioTelemetry Q4 Earnings Preview   [10:15AM  Benzinga]
▶ Stocks Showing Improved Relative Strength: BioTelemetry   [Dec-20-17 03:00AM  Investor's Business Daily]
▶ Apple Doesn't Need Next Big Thing For A While, Analyst Says   [Nov-30-17 04:31PM  Investor's Business Daily]
▶ BioTelemetry reports 3Q loss   [Nov-07-17 05:39PM  Associated Press]
▶ Stocks With Rising Relative Strength: BioTelemetry   [Oct-27-17 03:00AM  Investor's Business Daily]
▶ BioTelemetry: Cramer's Top Takeaways   [Oct-04-17 06:45AM  TheStreet.com]
▶ Does BioTelemetry Incs (BEAT) PE Ratio Warrant A Buy?   [Sep-15-17 11:43AM  Simply Wall St.]
▶ BioTelemetry posts 2Q profit   [Aug-08-17 11:04PM  Associated Press]
▶ Heart-Felt Buys: 6 Cardiac Opportunities   [Aug-03-17 02:05PM  Forbes]
▶ ETFs with exposure to BioTelemetry, Inc. : August 1, 2017   [Aug-01-17 04:16PM  Capital Cube]
▶ BioTelemetry completes $280M acquisition   [Jul-14-17 02:20PM  American City Business Journals]
▶ S&P, Dow Reach Record Highs; 4 Top-Rated Stocks Hit Buy Points   [01:35PM  Investor's Business Daily]
▶ BioTelemetry, Inc. Completes LifeWatch AG Acquisition   [Jul-12-17 11:00AM  GlobeNewswire]
▶ ETFs with exposure to BioTelemetry, Inc. : July 10, 2017   [Jul-10-17 02:02PM  Capital Cube]
▶ ETFs with exposure to BioTelemetry, Inc. : June 27, 2017   [Jun-27-17 02:57PM  Capital Cube]
Financial statements of BEAT
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.